SUSPECT ADVERSE REACTION REPORT

DO-TOLMAR, INC.-24DO048813

I. REACTION INFORMATION

1. PATIENT INITIALS (first, last)	1a. COUNTRY	2. DATE OF BIRTH			2a. AGE Years	3. SEX	4-6 REACTION ONSET			8-12 CHECK ALL APPROPRIATE TO ADVERSE REACTION
		Day	Month	Year			Day	Month	Year	
DPA	DOMINICAN Cont..	25	Jan	1948	77	Male			2025	

7+13 DESCRIBE REACTION(S) (including relevant tests/lab data)

1) Stroke (Cerebrovascular accident (10008190), Cerebrovascular accident (10008190))
Recovering/Resolving
2) Treatment discontinuation (Therapy cessation (10065154), Therapy cessation (10065154))
(//2025 -) - Unknown

- ☐ PATIENT DIED
- ☐ LIFE THREATENING
- ☐ INVOLVED OR PROLONGED INPATIENT HOSPITALIZATION
- ☐ RESULTS IN PERSISTENCE OR SIGNIFICANT DISABILITY/INCAPACITY
- ☐ CONGENITAL ANOMALY
- ☑ OTHER MEDICALLY IMPORTANT CONDITION

II. SUSPECT DRUG(S)INFORMATION

14. SUSPECT DRUG(S)(include generic name)

1) Eligard® (Leuprolide acetate, Leuprolide acetate) (Suspect) (45 Milligram, Injection)(Unknown) Cont..

20. DID EVENT ABATE AFTER STOPPING DRUG? ☐ YES ☐ NO ☑ NA

15. DAILY DOSE(S)

1) (45 milligram(s), 1 in 6 Month)

16. ROUTE(S) OF ADMINISTRATION

1) Subcutaneous

21. DID EVENT REAPPEAR AFTER REINTRODUCTION ☐ YES ☐ NO ☑ NA

(NA : Not Applicable)

17. INDICATION(S) FOR USE

1) Prostate cancer [10060862 - Prostate cancer]

18. THERAPY DATE(S) (from/to)	19. THERAPY DURATION
1) (04/May/2023 - //2025)	

III. CONCOMITANT DRUG(S) AND HISTORY

22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction)

No concomitants used/reported

23. OTHER RELEVANT HISTORY (e.g. diagnostics, allergies, pregnancy with last month of period, etc.)

1) PROSTATE CANCER (10060862, Prostate cancer) (Continuing: Yes)

IV. MANUFACTURER INFORMATION

24a. NAME AND ADDRESS OF MANUFACTURER

Name : Tolmar, Inc
701 Centre Avenue
Fort Collins, CO, 80526, UNITED STATES OF AMERICA
Anjan.Chatterjee@tolmar.comand+1--9702124900

Study Information
Study Name: NA
EudraCT Number:
Protocol No.: NA
Center No.:
Subject Id :

24.REPORT NULLIFIED	24b. MFR CONTROL NO.
☐ YES ☐ NO	DO-TOLMAR, INC.-24DO048813
24c. DATE RECEIVED BY MANUFACTURER: 27/Jun/2025	24d. REPORT SOURCE: ☑ STUDY ☐ LITERATURE ☐ HEALTH PROFESSIONAL
DATE OF THIS REPORT: 03/Jul/2025	25a. REPORT TYPE: ☐ INITIAL ☑ FOLLOWUP

= Continuation attached sheet(s)..

Continuation Sheet for CIOMS report

1a. COUNTRY

DOMINICAN REPUBLIC

7+13 DESCRIBE REACTION(S) (including relevant tests/lab data) (Continuation...)

Event Description :

This Study report from DOMINICAN REPUBLIC was received by Adium via the Patient Support Program "ASOFARMA A TU LADO" (Reference number: DO-ADIUM-DO-0029-20240426) on 26-APR-2024 from a Patient Family Member regarding an Elderly 76 Years old Male patient who experienced a serious (medically significant) event oof "Stroke" (Cerebrovascular accident), during Eligard (Leuprolide acetate) 45 milligram therapy for Prostate cancer. The needle component of the constituent device was not identified in the report. The report was sent to Tolmar on 27-APR-2024.

The patient's medical history and current conditions included Prostate cancer.

Concomitant medications were not reported.

On 04-MAY-2023, the patient began receiving Eligard 45 milligram, q 6 month via Subcutaneous use for Prostate cancer (Lot numbers and Expiration dates were not provided). On an unspecified date, approximately more than 6 months ago, the patient experienced cerebrovascular accident, for that reason they decided to stop the Eligard medication, in the month of MAY-2024, the patient will go to the Urologist to see how they will proceed with the patient.

Corrective treatment was not reported.

Action taken with Eligard in response to the event was Drug Withdrawn. De-challenge and re-challenge were not applicable.

The outcome of Cerebrovascular accident was Recovering.

The reporter did not assess the seriousness or causality of the event in relationship to Eligard and Eligard Unspecified Device.

Evaluator Comment (Tolmar): This 76 years old male patient had Cerebrovascular accident (cerebrovascular accident) during Eligard (Leuprolide acetate) 45 milligram therapy for Prostate cancer. Tolmar assessed Cerebrovascular accident as medically significant based on its nature. Cerebrovascular accident as related to Eligard drug (not related to device) based on temporal relation and known safety profile of the drug. Hypercoagulable state due to cancer provides more plausible explanation than suspect therapy. Elderly age was a risk factor.

On 27-Jun-2025, follow-up information from Brazil was received by Adium via an electronic form through the Jazz Safety tool of the "ASOFARMA A TU LADO" Patient Support Program (Reference number: DO-ADIUM-DO-0029-20240426) from the patient's son (non-healthcare professional) and sent to Tolmar on 27-Jun-2025. New information included: Added a non-serious event of “treatment discontinuation ' (Therapy cessation).

On an Unknown date in 2025, reporter confirmed that, the treatment was discontinued.

Corrective treatment was not reported.

Action taken with Eligard in response to the event was unknown. De-challenge and re-challenge were not applicable.

The outcome of Therapy cessation was Unknown.

The reporter did not assess the seriousness of Therapy cessation.

The reporter assessed the causality of the Therapy cessation in relationship to Eligard as related and not reported with Eligard Unspecified device.

No follow up queries were raised.

Therapy cessation>Eligard>Unlisted as per CCDS>07-Nov-2024
Therapy cessation>Eligard>Unlisted as per USPI>Feb-2025
Therapy cessation>Eligard unspecified device>Unlisted as per USPI>Feb-2025
Therapy cessation>Eligard>Unlisted as per Canadian monograph>02-Apr-2025

Company Remarks (Sender's Comments) :

Evaluator Comment (Tolmar): This 76 years old male patient had Cerebrovascular accident (cerebrovascular accident) during Eligard (Leuprolide acetate) 45 milligram therapy for Prostate cancer. Tolmar assessed Cerebrovascular accident as medically significant based on its nature. Cerebrovascular accident as related to Eligard drug (not related to device) based on temporal relation and known safety profile of the drug. Hypercoagulable state due to cancer provides more plausible explanation than suspect therapy. Elderly age was a risk factor.
Evaluator comment (Tolmar): The case is regarding an elderly 77 years old male patient who experienced a non-serious event of therapy cessation (treatment discontinuation), during Eligard (leuprolide acetate) 45 milligram therapy for prostate cancer. Tolmar assessed the reported event as non-

Continuation Sheet for CIOMS report

serious since it did not meet the ICH seriousness criteria and is not IME event. The reported event therapy cessation is assessed as not related with Eligard (drug and device) components as it would be due to human action (decision), rather due to the product.

14.SUSPECT DRUG(S) (Continuation...)

Product-Reaction Level

1) Drug : Eligard® (Leuprolide acetate)
Active Substance : 1) Leuprolide acetate
Drug Characterization : Suspect
Form Strength : 1) 45 Milligram
Form of Admin : 1) Injection
Lot Number : 1) Unknown
Daily Dose : (45 milligram(s), 1 in 6 Month)
Route of Admin : 1) Subcutaneous
Indications : 1) Prostate cancer [10060862 - Prostate cancer]
Therapy Dates : 1) From : 04/May/2023 To ://2025
Action(s) Taken With Drug : Drug withdrawn

Causality

1) Stroke (Cerebrovascular accident - 10008190, Cerebrovascular accident - 10008190)
Causality as per reporter : Not Reported
Causality as per Mfr : Related
DeChallenge : Not applicable
ReChallenge : Not Applicable
2) Treatment discontinuation (Therapy cessation - 10065154, Therapy cessation - 10065154)
Causality as per reporter : Related
Causality as per Mfr : Not Related
DeChallenge : Not applicable
ReChallenge : Not Applicable

Labeling :

1) Stroke
CORE Labeled
2) Treatment discontinuation
CORE UnLabeled

2) Drug : Eligard® Unspecified Device (Leuprolide acetate)
Active Substance : 1) Leuprolide acetate
Drug Characterization : Suspect
Form Strength : 1) 45 Milligram
Form of Admin : 1) Injection
Lot Number : 1) Unknown
Route of Admin : 1) Subcutaneous
Indications : 1) Prostate cancer [10060862 - Prostate cancer]
Action(s) Taken With Drug : Not applicable

Causality

1) Stroke (Cerebrovascular accident - 10008190, Cerebrovascular accident - 10008190)
Causality as per reporter : Not Reported
Causality as per Mfr : Not Related
DeChallenge : Not applicable
ReChallenge : Not Applicable
2) Treatment discontinuation (Therapy cessation - 10065154, Therapy cessation - 10065154)
Causality as per reporter : Not Reported
Causality as per Mfr : Not Related
DeChallenge : Not applicable
ReChallenge : Not Applicable

Labeling :

1) Stroke
CORE
2) Treatment discontinuation
CORE

15. DAILY DOSE(S) (Continuation...)

Continuation Sheet for CIOMS report

Dosage Text :
Drug 1 :Eligard®
1) 45 milligram, q 6 month